Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium 1

3367 - A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)


08 Oct 2016


Presidential Symposium 1


Mansoor Raza Mirza


Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/mdw435


M.R. Mirza1, B.J. Monk2, A. Oza3, S. Mahner4, A. Redondo5, M. Fabbro6, J. Ledermann7, D. Lorusso8, I.B. Vergote9, O. Rosengarten10, J. Berek11, J. Herrstedt12, A.V. Tinker13, A. Dubois14, A. Gonzalez Martin15, P. Follana16, B. Benigno17, B.J. Rimel18, S. Agarwal19, U. Matulonis20

Author affiliations

  • 1 Department Of Oncology 5073, NSGO & Rigshospitalet-Copenhagen University Hospital, 2100 - Copenhagen/DK
  • 2 Department Of Oncology, University of Arizona Cancer Center-Phoenix, Phoenix/US
  • 3 Department Of Oncology, University Health Network, Toronto/CA
  • 4 Department Of Gynegology, AGO & University of Munich, Hamburg/DE
  • 5 Department Of Oncology, GEICO & Hospital Universitario, Madrid/ES
  • 6 Department Of Oncology, GINECO & Institut du Cancer de Montpellier, Montpellier/FR
  • 7 Department Of Medical Oncology, NCRI & University College London, London/GB
  • 8 Department Of Gynecologic Oncology, MITO/MaNGO & Fondazione IRCCS National Cancer Institute, Milano/IT
  • 9 Department Of Obstetrics And Gynecology, BGOG & University of Leuven, Leuven/BE
  • 10 Department Of Gynecologic Oncology, ISGO & Sha’are Zedek Medical Center, Jerusalem/IL
  • 11 Department Of Oncology, Stanford Women’s Cancer Center, Stanford/US
  • 12 Department Of Oncology, NSGO & Odense University Hospital, Odense/DK
  • 13 Department Of Medicine, British Columbia Cancer Agency, Vancouver/CA
  • 14 Department Of Oncology, AGO & Kliniken Essen Mitte, Essen/DE
  • 15 Medical Oncology Department, GEICO & MD Anderson Cancer Center Madrid, Madrid/ES
  • 16 Department Of Medical Oncology, GINECO & Centre Antoine Lacassagne, Nice/FR
  • 17 Department Of Gynecologic Oncology, University Gynecologic Oncology, Atlanta/US
  • 18 Department Of Obstetrics And Gynecology, Cedars-Sinai Medical Center, West Hollywood/US
  • 19 Department Of Medical Affairs, Tesaro, Inc, 02451 - Waltham/US
  • 20 Department Of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3367


Niraparib is an oral, highly selective inhibitor of PARP1/2. This is the first randomized phase 3 trial of a PARP inhibitor as maintenance therapy post-platinum chemotherapy in patients (pts) with platinum-sensitive recurrent ovarian cancer.


Two independent cohorts were enrolled based on results of BRACAnalysis® testing: pts with a germline BRCA mutation (gBRCAmut), and pts who lacked these mutations (non-gBRCAmut). Within each cohort, pts were randomized (2:1) to receive niraparib 300 mg or placebo once daily. Three prospectively-defined populations were assessed: 1) the gBRCAmut cohort; 2) those in the non-gBRCAmut cohort whose tumors were retrospectively defined as deficient in homologous recombination (HRD) by the myChoice® HRD test; 3) the overall non-gBRCAmut cohort.


553 pts were enrolled in this international trial. 60% of pts had 2 lines of prior therapy, and 40% of pts had >2 prior lines. 76% of pts had stage IIIc or IV disease. Niraparib prolonged progression-free survival (PFS) as compared to placebo in all three pt populations (Table 1). Secondary endpoints of chemotherapy-free interval (CFI), time to first subsequent treatment (TFST), and PFS 2 also showed statistically significant improvement. Patient-reported outcomes (PRO) were similar for niraparib and placebo. Most common (≥10%) treatment-emergent grade 3/4 adverse events in niraparib-treated pts were thrombocytopenia (28%), anaemia (25%), and neutropenia (11%). There were no deaths during study treatment.

Progression-free Survival

gBRCAmut n = 203 non-gBRCAmut n = 350 non-gBRCAmut HRDpos n = 162
Niraparib n = 138 Placebo n = 65 Niraparib n = 234 Placebo n = 116 Niraparib n = 106 Placebo n = 56
PFS Median, Months (95% CI) 21.0 (12.9, NR) 5.5 (3.8, 7.2) 9.3 (7.2, 11.2) 3.9 (3.7, 5.5) 12.9 (8.1, 15.9) 3.8 (3.5, 5.7)
p value


Niraparib significantly improved PFS for all study populations as well as significantly prolonging CFI, TFST and PFS 2 with a manageable safety profile and without adversely impacting PRO.

Clinical trial identification


Legal entity responsible for the study

Tesaro Inc.


Tesaro, Inc.


B.J. Monk: Consultant for GSK, Merck, Tesaro, Genentech, AZ, Gradalis, Advaxis, Verastem, Cerulean, Amgen, Vermillion, Immunogen, Bayer, NuCana BioMed, Insys Therapeutics, Clovis Oncology, Oxigene, Pfizer – Speaker for Genentech, AZ, Janssen, Myriad Genetics. A. Oza: Consultant for Amgen, Verastem, Clovis Oncology, Immunovaccine. S. Mahner: Consultant for Roche, AZ, MSD, Jansen-Cilag, Tesaro, Medac – Honorarium from Roche/Genentech, AZ, PharmaMar, Medac, Jenapharm, Janssen-Cilag, Teva, GSK – Research support from Roche, AZ, BI, GSK, Janssen-Cilag, Medac, PharaMar, Tesaro, Bayer. A. Redondo: Consultant for Roche, PharaMar – Honorarium from Roche – Speaker for Roche. M. Fabbro: Has received travel support from Roche. J. Ledermann: Consultant for AZ/MedImmune, Clovis Oncology – Research support from AZ. D. Lorusso: Consultant for AZ, PharaMar, Roche Glycart – Speaker for PharmaMar – travel support from PharaMar, Roche Glycart. I.B. Vergote: Consultant & researcher for AZ, Amgen NV, Array Biopharma, Biogen, BI, BMS, Esai, Lilly, Endocye, Genentech, GSK, Janssen-Cilag, Medimmune, MSD, Morphotek, Nektar, Novo Nordisk, Oasmia, PharaMar, Roche, Sanofi, Shering-Plough, Sigma-Tau, among others. J. Berek: Consultant for Prima BioMed, Atara Biotherapeutics – Research support from Tesaro, Quest Diagnostics, Endocyte, Genentech, AZ, Prima BioMed. J. Herrstedt: Consultant for Tesaro. A.V. Tinker: Consultant for AZ – Research support from AZ/MedImmune. A. Dubois: Consultant for AZ, PharaMar, Roche/Genentech, Mundipharma, Pfizer. A. Gonzalez Martin: Consultant for PharaMar, Roche Glycart, - Speaker for AZ, PharaMar, Roche Glycart P. Follana: Has received travel support from AZ and Roche Glycart. B. Benigno: Consultant for Genentech – Speaker for and received honorarium from AZ, Insys Therapeutics – Travel support from AZ. B.J. Rimel: Consultant for AZ – Received Honorarium from Genentech S. Agarwal: Is an employee of Tesaro. U. Matulonis: Consultant for Merck KGaA, AZ, Immunogen, Tesaro, Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.